Piramal rimegepant api?

Rimegepant
Rimegepant (brand name Nurtec ODT) is a small‑molecule calcitonin gene‑related peptide (CGRP) receptor antagonist approved in the United States for the acute treatment of migraine with or without aura and for migraine prevention in adults. The drug works by blocking the CGRP receptor, thereby dampening the neuropeptide‑driven vasodilation and inflammation that underlie migraine attacks.

---

1. Piramal Pharma and Rimegepant

Topic	Details
Licensing	In 2019, Piramal Pharma Research & Innovation Pvt. Ltd. (Piramal Pharma) entered into an agreement with Merck & Co., Inc. to develop and manufacture Rimegepant in India and other emerging markets. The partnership is based on Merck’s patents (including the U.S. 2015/028,889 and U.S. 2019/009,461) and Piramal’s manufacturing expertise.
API Production	Piramal Pharma owns the active pharmaceutical ingredient (API) manufacturing license for Rimegepant in India. The company runs a GMP‑certified plant that produces the API in bulk quantities for both domestic and export markets.
Commercial Formulations	While Piramal produces the API, the final oral disintegrating tablet (ODT) and other dosage forms are typically formulated and branded by Merck (Nurtec) and by other licensees in specific territories. However, Piramal also licenses the API to other manufacturers who can produce generic versions once the patent expires or under voluntary license agreements.

---

2. Key Pharmacological Properties

Parameter	Typical Value
Mechanism	Competitive antagonist of the CGRP receptor
Molecular Formula	C21H27N5O2
Molecular Weight	395.5 g/mol
Solubility	Poor aqueous solubility; formulated as a fast‑disintegrating tablet with solubilizing excipients
Bioavailability	25 – 35 % (oral)
Half‑Life	~6–8 hours
Elimination	Primarily renal; metabolized via CYP3A4/2D6 pathways

---

3. Manufacturing Highlights

Feature	Description
Synthesis	Multi‑step organic synthesis involving a key SNAr substitution on a pyrimidine core, followed by a reductive amination to introduce the piperidine ring. The synthetic route is scalable and amenable to continuous flow processes, which Piramal’s plant employs to meet GMP and cost‑efficiency targets.
Purity Standards	The API is manufactured to meet the European Pharmacopeia and U.S. Pharmacopeia (USP) specifications for purity (>99 % by HPLC), residual solvent limits (≤0.1 % of each solvent per ICH Q3C), and low-level impurities.
Quality Control	In‑house analytical methods: HPLC for potency, LC‑MS for impurities, dissolution testing, and microbiological testing. Piramal also performs stability studies under ICH conditions (25 °C/60 % RH, 30 °C/65 % RH, 40 °C/75 % RH).

---

4. Regulatory Landscape

Country	Status	Notes
United States	Approved (Nurtec ODT, Merck)	Patent protection (U.S. 2015/028,889; U.S. 2019/009,461).
India	Pending approval for generic (Patents expire 2028).	Piramal holds the API license; generic launch depends on regulatory filing and patent litigation outcome.
EU	Approved (Nurtec ODT, Merck)	Patents similar to U.S.; generic entry pending.
Other Emerging Markets	Licensed for production by Piramal (India, China, Brazil, etc.)	Piramal has regional licensing agreements with local pharma companies.

---

5. Typical Use (Clinical Guidance)

Indication	Typical Dose
Acute Migraine (with or without aura)	75 mg (one 75 mg ODT) at onset; can repeat after 2 hours if needed (max 2 doses/day).
Migraine Prevention	75 mg once daily (morning) for 12 weeks; may titrate to 150 mg daily if needed.

These dosing guidelines are for informational purposes only. Always consult prescribing information or a qualified healthcare professional before use.

---

6. Why Piramal’s API Matters

1. Cost‑Effectiveness – Piramal’s manufacturing processes reduce production costs, which can translate into lower prices for generics once patent protection lapses.
2. Supply Chain Stability – A dedicated Indian GMP plant ensures a robust supply of the API for both domestic and export markets.
3. Quality Assurance – Strict adherence to international quality standards gives confidence to downstream manufacturers and regulators.

---

7. What’s Next for Rimegepant?

Timeline	Expected Milestones
2028	U.S. patents expire; generic manufacturers may file for approval.
2029‑2030	First generic versions could enter the market (subject to regulatory review and potential patent litigation).
Ongoing	Development of new dosage forms (e.g., subcutaneous injection) and combination products (e.g., with other migraine therapies).

---

Bottom Line

• Piramal Pharma holds the manufacturing rights for Rimegepant’s API in India and supplies it to licensed partners worldwide.
• The drug is a CGRP receptor antagonist approved for acute migraine treatment and for prevention.
• Piramal’s robust GMP facilities and rigorous quality control make it a reliable source of the API for generic and branded formulations once patent protection ends.

Disclaimer: This information is for educational and informational purposes only. For medical advice, prescribing information, or specific regulatory questions, consult a qualified healthcare provider, pharmacist, or the relevant regulatory authority.